Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

DiaSorin

BATS-CHIXE:DIAM
Snowflake Description

Solid track record with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DIAM
BATS-CHIXE
€7B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
DIAM Share Price and Events
7 Day Returns
-0.8%
BATS-CHIXE:DIAM
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
29.2%
BATS-CHIXE:DIAM
-0.3%
GB Medical Equipment
-23.6%
GB Market
DIAM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DiaSorin (DIAM) -0.8% 13.4% -0.4% 29.2% 79.6% 184.2%
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • DIAM outperformed the Medical Equipment industry which returned -0.3% over the past year.
  • DIAM outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
DIAM
Industry
5yr Volatility vs Market

DIAM Value

 Is DiaSorin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of DiaSorin to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for DiaSorin.

BATS-CHIXE:DIAM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.7%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:DIAM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 8.2%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 24%) (0%))
0.871
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.87
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.871 * 8.23%)
7.7%

Discounted Cash Flow Calculation for BATS-CHIXE:DIAM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for DiaSorin is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:DIAM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.7%)
2020 168.74 Analyst x5 156.68
2021 181.12 Analyst x5 156.15
2022 200.00 Analyst x4 160.10
2023 245.00 Analyst x1 182.10
2024 265.00 Analyst x1 182.88
2025 278.78 Est @ 5.2% 178.64
2026 289.37 Est @ 3.8% 172.17
2027 297.52 Est @ 2.82% 164.36
2028 303.86 Est @ 2.13% 155.87
2029 308.88 Est @ 1.65% 147.11
Present value of next 10 years cash flows €1,656.00
BATS-CHIXE:DIAM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €308.88 × (1 + 0.53%) ÷ (7.7% – 0.53%)
€4,331.07
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €4,331.07 ÷ (1 + 7.7%)10
€2,062.81
BATS-CHIXE:DIAM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €1,656.00 + €2,062.81
€3,718.81
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €3,718.81 / 54.66
€68.04
BATS-CHIXE:DIAM Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:DIAM represents 0.94555x of BIT:DIA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.94555x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 68.04 x 0.94555
€64.33
Value per share (EUR) From above. €64.33
Current discount Discount to share price of €118.10
= -1 x (€118.10 - €64.33) / €64.33
-83.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of DiaSorin is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DiaSorin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DiaSorin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:DIAM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €2.94
BIT:DIA Share Price ** BIT (2020-04-06) in EUR €124.9
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DiaSorin.

BATS-CHIXE:DIAM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BIT:DIA Share Price ÷ EPS (both in EUR)

= 124.9 ÷ 2.94

42.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • DiaSorin is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does DiaSorin's expected growth come at a high price?
Raw Data
BATS-CHIXE:DIAM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 42.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
7%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:DIAM PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 42.54x ÷ 7%

6.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on DiaSorin's assets?
Raw Data
BATS-CHIXE:DIAM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €13.60
BIT:DIA Share Price * BIT (2020-04-06) in EUR €124.9
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:DIAM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BIT:DIA Share Price ÷ Book Value per Share (both in EUR)

= 124.9 ÷ 13.60

9.18x

* Primary Listing of DiaSorin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess DiaSorin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. DiaSorin has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DIAM Future Performance

 How is DiaSorin expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DiaSorin expected to grow at an attractive rate?
  • DiaSorin's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • DiaSorin's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • DiaSorin's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:DIAM Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:DIAM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 7%
BATS-CHIXE:DIAM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 6.3%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:DIAM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:DIAM Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 959 309 246 3
2023-12-31 899 285 224 3
2022-12-31 854 276 207 5
2021-12-31 795 252 191 6
2020-12-31 720 235 166 6
2020-04-07
BATS-CHIXE:DIAM Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 706 233 176
2019-09-30 700 248 168
2019-06-30 688 214 161
2019-03-31 675 220 160
2018-12-31 669 210 158
2018-09-30 663 175 161
2018-06-30 649 179 154
2018-03-31 644 154 145
2017-12-31 637 167 140
2017-09-30 625 174 125
2017-06-30 622 174 125
2017-03-31 602 183 121

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DiaSorin's earnings are expected to grow by 7% yearly, however this is not considered high growth (20% yearly).
  • DiaSorin's revenue is expected to grow by 6.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:DIAM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from DiaSorin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:DIAM Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.44 4.90 3.98 2.00
2023-12-31 4.05 4.43 3.78 3.00
2022-12-31 3.71 4.00 3.50 3.00
2021-12-31 3.45 3.66 3.25 6.00
2020-12-31 3.05 3.19 2.79 8.00
2020-04-07
BATS-CHIXE:DIAM Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31
2019-09-30
2019-06-30 2.94
2019-03-31
2018-12-31 2.85
2018-09-30
2018-06-30 2.78
2018-03-31
2017-12-31 2.54
2017-09-30
2017-06-30 2.28
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • DiaSorin is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess DiaSorin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DiaSorin has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DIAM Past Performance

  How has DiaSorin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DiaSorin's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DiaSorin's year on year earnings growth rate has been positive over the past 5 years.
  • DiaSorin's 1-year earnings growth is less than its 5-year average (11.1% vs 14.8%)
  • DiaSorin's earnings growth has exceeded the GB Medical Equipment industry average in the past year (11.1% vs -9.5%).
Earnings and Revenue History
DiaSorin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DiaSorin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:DIAM Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 706.30 175.70 212.40 47.90
2019-09-30 700.30 168.03 211.93 46.08
2019-06-30 688.28 161.31 208.68 46.15
2019-03-31 675.50 160.23 205.73 45.08
2018-12-31 669.20 158.13 200.83 45.08
2018-09-30 662.89 160.98 197.05 44.73
2018-06-30 649.40 154.26 192.24 44.29
2018-03-31 644.49 145.28 189.35 45.13
2017-12-31 637.49 139.88 188.35 43.63
2017-09-30 624.61 125.38 185.32 43.12
2017-06-30 622.35 124.91 183.50 42.59
2017-03-31 602.31 120.58 178.02 40.72
2016-12-31 569.31 112.38 170.12 37.72
2016-09-30 544.08 111.06 163.64 34.15
2016-06-30 520.27 105.50 158.04 30.19
2016-03-31 506.04 102.49 154.93 27.29
2015-12-31 499.18 100.42 154.10 26.16
2015-09-30 486.35 94.76 150.76 25.37
2015-06-30 472.14 92.92 147.61 25.29
2015-03-31 455.50 86.99 143.77 25.11
2014-12-31 443.77 84.07 140.28 24.99
2014-09-30 436.72 83.55 139.10 24.79
2014-06-30 431.90 82.18 136.74 24.14
2014-03-31 434.93 82.30 137.16 23.87
2013-12-31 434.85 83.03 136.03 23.95
2013-09-30 432.54 81.50 133.95 23.76
2013-06-30 432.80 82.86 133.73 23.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • DiaSorin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • DiaSorin used its assets more efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • DiaSorin has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess DiaSorin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DiaSorin has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DIAM Health

 How is DiaSorin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DiaSorin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DiaSorin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DiaSorin's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of DiaSorin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are -12.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DiaSorin Company Filings, last reported 3 months ago.

BATS-CHIXE:DIAM Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 848.60 0.00 172.90
2019-09-30 810.80 0.00 132.80
2019-06-30 747.17 42.27 134.06
2019-03-31 754.70 0.00 78.30
2018-12-31 704.74 21.21 96.53
2018-09-30 756.80 0.00 128.80
2018-06-30 624.82 13.89 117.57
2018-03-31 771.60 0.00 168.60
2017-12-31 741.96 24.01 173.31
2017-09-30 699.50 0.00 113.30
2017-06-30 662.43 39.80 129.03
2017-03-31 693.50 0.00 114.10
2016-12-31 663.39 59.31 130.47
2016-09-30 616.76 64.12 110.68
2016-06-30 588.95 67.30 73.22
2016-03-31 602.00 2.30 292.14
2015-12-31 587.16 2.44 270.36
2015-09-30 552.18 2.22 233.82
2015-06-30 531.41 2.91 198.89
2015-03-31 544.19 4.09 224.31
2014-12-31 483.57 3.48 169.82
2014-09-30 459.12 3.33 148.01
2014-06-30 426.89 3.51 110.76
2014-03-31 434.20 7.16 132.21
2013-12-31 414.14 7.18 105.11
2013-09-30 395.59 8.31 92.36
2013-06-30 379.60 8.60 67.51
  • Unable to establish if DiaSorin's level of debt is high without past debt data.
  • Unable to establish if DiaSorin's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • DiaSorin has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess DiaSorin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DiaSorin has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DIAM Dividends

 What is DiaSorin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.76%
Current annual income from DiaSorin dividends. Estimated to be 0.97% next year.
If you bought €2,000 of DiaSorin shares you are expected to receive €15 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • DiaSorin's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • DiaSorin's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Upcoming dividend payment

Purchase DiaSorin before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:DIAM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:DIAM Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31 1.40 1.00
2023-12-31 1.42 2.00
2022-12-31 1.34 4.00
2021-12-31 1.22 6.00
2020-12-31 1.07 8.00
2020-04-07
BATS-CHIXE:DIAM Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-03-11 0.950 0.843
2019-04-02 0.900 0.862
2019-03-14 0.900 1.017
2018-03-07 0.850 1.027
2017-05-15 0.800 1.090
2016-04-07 0.650 1.149
2016-03-09 0.650 1.367
2015-03-30 0.600 1.394
2015-03-03 0.600 1.551
2014-04-01 0.550 1.761
2014-03-06 0.550 1.779
2012-11-07 0.500 1.628
2012-08-06 0.460 1.746
2012-08-03 0.460 1.860
2012-03-30 0.460 2.136
2012-03-12 0.460 2.178
2011-03-16 0.400 1.513
2011-02-14 0.400 1.233
2010-04-09 0.200 0.644
2009-04-14 0.120 0.557

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • DiaSorin is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of DiaSorin's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of DiaSorin's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • No need to calculate the sustainability of DiaSorin's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess DiaSorin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DiaSorin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DiaSorin has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DIAM Management

 What is the CEO of DiaSorin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carlo Rosa
COMPENSATION €1,330,000
AGE 53
TENURE AS CEO 14.3 years
CEO Bio

Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa led a management buy out with four other managers and a group of financial investors to buy DiaSorin from the previous owner, American Standard Inc. As a result, he became the Chief Operating Officer of DiaSorin until 2006. In 1990, he moved to New York to work at the Public Health Research Institute on a project aimed at the development of a new innovative product for diagnosing Hepatitis CV infections. In 1992, he joined Incstar Corporation, (MN) USA, an American Public Company and worked in the R&D department to lead a project in joint venture with Akzo Nobel. Then he held different positions both in the R&D and the Strategic Marketing departments until he took the role of Director of the Infectious Disease Business Unit. In 1998, he moved back to Italy to assume the role of Director of European S&M for DiaSorin Spa. Mr. Rosa serves as the Director at DiaSorin Inc. In 2014, he was nominated as Vice Chairman of Alisei, a consortium of private and public Italian entities intended to promote the development of Life Science in Italy. Mr. Rosa serves as a Member of Scientific Advisory Board at Life Care Capital S.p.A. Mr. Rosa graduated in 1990 in Chemistry from the University of Torino summa cum laude.

CEO Compensation
  • Carlo's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Carlo's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the DiaSorin management team in years:

4.1
Average Tenure
54.5
Average Age
  • The tenure for the DiaSorin management team is about average.
Management Team

Carlo Rosa

TITLE
CEO, GM & Executive Director
COMPENSATION
€1M
AGE
53
TENURE
14.3 yrs

Chen Even

TITLE
Chief Commercial Officer
COMPENSATION
€663K
AGE
56
TENURE
4.3 yrs

Piergiorgio Pedron

TITLE
Corporate Accounting Documents Officer
AGE
48
TENURE
3.9 yrs

Riccardo Fava

TITLE
Senior Director of Investor Relations & Corporate Communication

Marco Minolfo

TITLE
Manager of the Corporate Legal Affairs Department

Stefano Ronchi

TITLE
Senior Corporate Vice President of Human Resources
AGE
59

John Gerace

TITLE
President of DiaSorin Molecular LLC
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the DiaSorin board of directors in years:

8.5
Average Tenure
54.5
Average Age
  • The tenure for the DiaSorin board of directors is about average.
Board of Directors

Gustavo Denegri

TITLE
Chairman
COMPENSATION
€400K
AGE
82
TENURE
10 yrs

Carlo Rosa

TITLE
CEO, GM & Executive Director
COMPENSATION
€1M
AGE
53
TENURE
13.1 yrs

Michele Denegri

TITLE
Deputy Chairman
COMPENSATION
€150K
AGE
50
TENURE
7 yrs

Chen Even

TITLE
Chief Commercial Officer
COMPENSATION
€663K
AGE
56
TENURE
13.1 yrs

Francesco Moscetti

TITLE
Independent Director
COMPENSATION
€55K
AGE
68
TENURE
13.1 yrs

Giuseppe Alessandria

TITLE
Lead Independent Director
COMPENSATION
€45K
AGE
77
TENURE
7 yrs

Monica Mannino

TITLE
Chairman of Board of Statutory Auditors
AGE
50
TENURE
4 yrs

Enrico Amo

TITLE
Non-Executive Director
COMPENSATION
€35K
AGE
63
TENURE
13.1 yrs

Roberta Somati

TITLE
Independent Director
COMPENSATION
€35K
AGE
50
TENURE
7 yrs

Stefano Altara

TITLE
Non-Executive Director
COMPENSATION
€35K
AGE
52
TENURE
6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Dec 19 Sell Carlo Rosa Individual 17. Dec 19 19. Dec 19 -50,000 €117.42 €-5,862,247
19. Dec 19 Sell Chen Even Individual 18. Dec 19 18. Dec 19 -2,300,000 €1.60 €-3,689,200
13. Dec 19 Sell Chen Even Individual 09. Dec 19 11. Dec 19 -26,000 €122.14 €-3,164,551
X
Management checks
We assess DiaSorin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DiaSorin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DIAM News

Simply Wall St News

DIAM Company Info

Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide. The company offers tests for diagnosis in a range of clinical areas, such as infectious diseases, gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various technological platforms, including LIAISON XL and LIAISON XS analyzer systems; and LIAISON MDX instrument, a thermocycler. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Details
Name: DiaSorin S.p.A.
DIAM
Exchange: BATS-CHIXE
Founded: 1968
€6,826,690,525
54,657,250
Website: http://www.diasoringroup.com
Address: DiaSorin S.p.A.
Via Crescentino,
Saluggia,
Vercelli, 13040,
Italy
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BIT DIA Common Shares Borsa Italiana IT EUR 19. Jul 2007
OTCPK DSRL.F Common Shares Pink Sheets LLC US USD 19. Jul 2007
DB 34D Common Shares Deutsche Boerse AG DE EUR 19. Jul 2007
LSE 0GZX Common Shares London Stock Exchange GB EUR 19. Jul 2007
BATS-CHIXE DIAM Common Shares BATS 'Chi-X Europe' GB EUR 19. Jul 2007
Number of employees
Current staff
Staff numbers
1,950
DiaSorin employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 19:39
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.